Case report of short term EGFR TKI induced tubulointerstitial nephritis and IgA nephropathy in a patient with advanced non small cell lung cancer.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the front-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC). Beyond their long-term effects and safety profile, they are a landmark of precision medicine in the history of NSCLC. Regarding safety outcomes, EGER TKIs differ from cytotoxic chemotherapy as they may cause dermatological adverse events, diarrhea, and fetal interstitial pneumonitis. They are mainly metabolized by the liver and to a lesser extent by the kidney and are therefore considered relatively safe to use, even in patients with renal impairment. Moreover, renal adverse events have been rarely described in patients treated with TKIs; in particular, only a few cases of EGFR TKI-induced IgA nephropathy have been reported. Herein, we report a case of EGFR TKI-induced tubulointerstitial nephritis and IgA nephropathy, aggravating renal function with short-term EGFR TKI use in EGFR-mutant NSCLC.